CAR T-cell therapy in Lymphocytic Leukemia - A Pipeline Analysis Report

This pipeline analysis report provides detailed insights into the clinical trials landscape of the drug development for CAR T-cell therapy in Lymphocytic Leukemia including molecules at pre-clinical, Phase I, and Phase I/II stage. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapy, route of administration, by territory, therapeutic modality, and target.

Overview of the drug development pipeline for CAR T-cell therapy in Lymphocytic Leukemia  

Leukemia is the cancer of blood cells, that degenerates the death of damaged cells in comparison to normal cells. Leukemia is diversified into myeloid leukemia, occurring in the myeloid cells, or lymphocytic leukemia, occurring in the bone marrow. Lymphocytic leukemia occurs during the early formation time of the lymphocytes in the bone marrow. It is further segregated into chronic lymphocytic leukemia (CLL) or acute lymphocytic leukemia (ALL). CLL progresses over a period of months or years, whereas ALL progresses quickly and becomes fatal if left untreated. This disease inflicts those with higher genetic chances of developing CLL or ALL. Technavio’s market research analysts have predicted that with the increased effectiveness against cancer cells, various CAR T-cell therapies are being developed for both forms of leukemia. This pipeline analysis identifies that the most common target for CAR T-cell therapies for leukemia is CD19.   

According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the Phase I and Phase I/II drug development stage. Our market research analysts have also identified that these molecule segments are followed by the pre-clinical drug development phase. The pipeline landscape in the pipeline analysis report also mentions the same percentage of drug development molecules that are in phase II and phase III drug development stages.   

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug development molecules for the treatment of CAR T-cell therapy in Lymphocytic Leukemia. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are:

• Novartis
• Cellectis
• Immune Cell

Therapeutic assessment of the drug development pipeline for CAR T-cell therapy in Lymphocytic Leukemia by route of administration

• Intravenous

The intravenous route of administration (ROA) involves the administration of drug substances directly into a vein. It has been observed that the majority of total therapeutics for lymphocytic leukemia are being developed for intravenous administration.

Therapeutic assessment of the drug development pipeline for CAR T-cell therapy in Lymphocytic Leukemia by therapies employed

• Monotherapy
• Monotherapy + combination therapy

According to this pipeline analysis report, majority of the therapies being employed for lymphocytic leukemia are being developed as monotherapy. Monotherapy consists of the use of a single drug to treat a particular disorder.  

Technavio also offers customization on reports based on specific client requirement.